SOPH - SOPHiA GENETICS SA
| Previous Close | 4.2600 |
| Open | 4.2700 |
| Bid | 4.3900 x 800 |
| Ask | 4.4400 x 900 |
| Day's Range | 4.2700 - 4.5900 |
| 52 Week Range | 1.6850 - 5.7700 |
| Volume | |
| Avg. Volume | 120,850 |
| Market Cap | 284.319M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings Date | May 09, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
Simply Wall St.Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ZacksSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -10.71% and 4.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireSOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023
Strong growth momentum and efficient expense execution continuesBOSTON and LAUSANNE, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue for the first quarter of 2023 was $14.0 million, representing year-over-year growth of 29% on a reported basis over the corresponding period of 2022; Constant currency year-o
Business WireSOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited
BOSTON & LAUSANNE, Switzerland, May 03, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of cancer
Business WireSOPHiA GENETICS Celebrates Swiss Biotech Award
BOSTON & LAUSANNE, Switzerland, April 25, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award recognizes SOPHiA GENETICS’ contributions in leading the way to democratizing data-driven medicine.
- GlobeNewswire
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST. The call will be webcast
Business WireThe University of Maryland Medical Center Chooses SOPHiA GENETICS Technology
BOSTON & LAUSANNE, Switzerland, April 18, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their capabilities around rare disease detection and treatment. UMMC has chosen SOPHiA Whole Exome Solution™ v2, a next-generation sequencing (NGS)-based application that provides a streamlined end-to-end work
- Simply Wall St.
SOPHiA GENETICS SA's (NASDAQ:SOPH) Share Price Matching Investor Opinion
SOPHiA GENETICS SA's ( NASDAQ:SOPH ) price-to-sales (or "P/S") ratio of 5.9x may look like a poor investment...
Business WireKrsnaa Diagnostics is Live on SOPHiA GENETICS
BOSTON & LAUSANNE, Switzerland, April 11, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Krsnaa Diagnostics, India’s largest diagnostic services provider in radiology and pathology, is live on SOPHiA DDM™ technology. Krsnaa Diagnostics is using the SOPHiA DDM™ for Hereditary Cancers Solution to expand their current next-generation sequencing (NGS) offerings.
Business WireTel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
BOSTON & LAUSANNE, Switzerland, April 04, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities. The facility, which serves a population of one million people, will use the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to h
Business WireAcutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
BOSTON & LAUSANNE, Switzerland, March 28, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
- Simply Wall St.
SOPHiA GENETICS SA (NASDAQ:SOPH) surges 23%; individual investors who own 44% shares profited along with institutions
Key Insights The considerable ownership by individual investors in SOPHiA GENETICS indicates that they collectively...
ZacksSOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?
SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ZacksSOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Business WireSOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
BOSTON & LAUSANNE, Switzerland, March 14, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.
- Thomson Reuters StreetEvents
Full Year 2022 Sophia Genetics SA Earnings Call
Full Year 2022 Sophia Genetics SA Earnings Call
- Zacks
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 35.29% and 3.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
BOSTON & LAUSANNE, Switzerland, March 07, 2023--SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022.
Business WireUniversity of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
BOSTON & LAUSANNE, Switzerland, March 06, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies.
Business WireSOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
BOSTON & LAUSANNE, Switzerland, March 03, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
- Reuters
Qiagen partners with Sophia Genetics on next-generation sequencing kits
Qiagen is to collaborate with Sophia Genetics on its next-generation sequencing (NGS) kits, the US-German pharmaceutical company said on Wednesday. The alliance, part of Qiagen's Qiqseq platform partnership program, aims to increase the compatibility of its NGS kits with third-party digital data-sharing and analytics companies. "The partnership with Sophia Genetics is planned to be expanded to other areas of analysis," it added.
Business WireSOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
BOSTON & LAUSANNE, Switzerland, March 01, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).
Business WireSynergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
BOSTON & LAUSANNE, Switzerland, February 28, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology portfolio while helping to further the U.S. oncology market.
Business WireSOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023
BOSTON & LAUSANNE, Switzerland, February 23, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. EST / 2:00 p.m. CET.
Business WireSOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
BOSTON & LAUSANNE, Switzerland, February 13, 2023--SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio. The multimodal approach will go beyond a single data modality, combining radiomics analysis of medical imaging data, molecular data, digital pathology, clinic